Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy.

Abstract

BACKGROUND:

In order to analyze the clinical activity and cost-effectiveness of granulocyte colony-stimulating factors (G-CSF), the prophylactic usage of G-CSF in patients treated with a single chemotherapy regimen during early courses was prospectively evaluated.

METHODS:

Thirty patients with newly diagnosed non-Hodgkin lymphoma (NHL) treated with the first course of an R-CHOP regimen were enrolled randomly. After treatment with the first course of chemotherapy, a daily dose of G-CSF (lenograstim, 100 μg) was administered to half (15 cases) of the patients, and a dose of G-CSF (100 μg) was administered every other day to the other half of the patients when leukocytopenia (<1.5 × 10(9)/L) and/or neutropenia (<0.5 × 10(9)/L) occurred. Changes in leukocyte and neutrophil counts, prophylaxis, febrile neutropenia (FN) events, and cost performance between the two groups were analyzed.

RESULTS:

No significant difference between the two groups was observed in recoveries of leukocyte and neutrophil counts and evidence of FN. The only difference was the total cost of G-CSF.

CONCLUSION:

We concluded that every-other-day use of G-CSF was as clinically effective for the prophylaxis of FN as the daily use of G-CSF, and economically speaking, the administration of G-CSF every other day should be more beneficial for patients with NHL during early courses of R-CHOP chemotherapy.

• Authors: Yoshihiro Yakushijin, Hisaharu Shikata, Ikue Takaoka, Tamami Horikawa, Kazuhito Takeuchi, Jun Yamanouchi, Taichi Azuma, Hiroshi Narumi, Takaaki Hato, Masaki Yasukawa
• Journal: International journal of clinical oncology (Int J Clin Oncol) Vol. 16 Issue 2 Pg. 118-24 (Apr 2011) ISSN: 1437-7772 [Electronic] Japan
• PMID: 20924633 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Antibiotics, Antineoplastic
• Recombinant Proteins
• Granulocyte Colony-Stimulating Factor
• Vincristine
• Lenograstim
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Aged
• Antibiotics, Antineoplastic (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects, therapeutic use)
• Cost-Benefit Analysis
• Cyclophosphamide (administration & dosage, adverse effects)
• Doxorubicin (administration & dosage, adverse effects)
• Drug Administration Schedule
• Female
• Fever (blood, drug therapy)
• Granulocyte Colony-Stimulating Factor (administration & dosage, economics)
• Humans
• Lenograstim
• Leukocytes (drug effects)
• Lymphoma, Large B-Cell, Diffuse (blood, drug therapy, economics)
• Male
• Middle Aged
• Neutropenia (blood, drug therapy, economics)
• Neutrophils (drug effects)
• Prednisone (administration & dosage, adverse effects)
• Recombinant Proteins (administration & dosage, economics)
• Vincristine (administration & dosage, adverse effects)